EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single‐Cell Transcriptomics Identifies BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma

Keyun Zhu iD, Mingrong Lin iD, Chengbin Lin, Tao Hu iD, Zhikai Cao iD, Shuo Huang iD, Yan Shen iD, Jing Zeng iD, Jinxian He iD, Weiyu Shen iD, Jianjian Ying iD

Mediators of Inflammation · 2026-01 · 2026 (1)

DOI: 10.1155/mi/3777132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 06.05.2026. Verfasst von Keyun Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated LiHuiLi Hospital of Ningbo University, Ningbo, 315040, Zhejiang, China, nbu.edu.cn. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Antigens, CD, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Ningbo, Medical Science and Technology Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung adenocarcinoma (LUAD) is a leading cause of cancer‐related mortality worldwide. The tumor microenvironment (TME) plays a pivotal role in LUAD progression, but the specific molecular mechanisms driving malignancy and immune evasion remain incompletely understood. Bone marrow stromal cell antigen 2 (BST2) has been implicated in other cancers, yet its functional role and therapeutic potential in LUAD require further elucidation.

Methods

We integrated single‐cell RNA sequencing (scRNA‐seq) data from primary LUAD tissues and normal lung tissues with bulk RNA‐seq data from The Cancer Genome Atlas (TCGA)–LUAD and GEO cohorts. Malignant epithelial cells were identified using inferCNV analysis. Cellular trajectory and cell–cell communication analyses were systematically performed to delineate the malignant transformation process and its interactions with the TME. High‐dimensional weighted gene coexpression network analysis further identified key functional modules within malignant subpopulations. The oncogenic role of BST2 was comprehensively validated through differential expression analysis, survival analysis, gene set enrichment analysis (GSEA), and in vitro cellular assays, including RT‑qPCR, MTT, colony formation, Transwell invasion, and wound healing experiments. In addition, we employed the tumor immune dysfunction and exclusion (TIDE) algorithm to evaluate its association with immunotherapy response and performed drug screening via the Clue.io platform to explore its therapeutic potential. Results scRNA‐seq analysis revealed significant heterogeneity in the TME and identified two distinct subpopulations of malignant epithelial cells. Trajectory analysis uncovered a specific lineage (Lineage 4) driving the normal‐to‐malignant transition, while cell communication analysis highlighted interactions between malignant cells and tumor‐associated macrophages (TAMs) mediated by MIF and APP signaling pathways. High‐dimensional weighted gene coexpression network analysis (hdWGCNA) identified a coexpression gene module (Module 1) specifically enriched in malignant subpopulations. By intersecting with a set of immunoregulatory genes, BST2 was ultimately determined as a key candidate oncogene. BST2 was significantly upregulated in malignant epithelial cells and TAMs, and its high expression was closely associated with poor patient prognosis. GSEA demonstrated that high BST2 expression was linked to the activation of crucial oncogenic pathways, including oxidative phosphorylation, Kras signaling, and epithelial–mesenchymal transition (EMT). In vitro validation further confirmed that BST2 knockdown suppressed LUAD cell proliferation, migration, and invasion. Furthermore, elevated BST2 expression was associated with reduced efficacy of immune checkpoint blockade (ICB) therapy.

Conclusion

Our study unveils BST2 as a critical oncogene in LUAD, promoting tumor progression and influencing the TME, particularly via TAM recruitment. BST2 expression predicts patient prognosis and immunotherapy response, positioning it as a promising biomarker and therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungAntigens, CDLung NeoplasmsImmunotherapyBiomarkers, TumorHumansBone Marrow Stromal Antigen 2GPI-Linked ProteinsTumor MicroenvironmentGene Expression Regulation, NeoplasticCell Line, TumorTranscriptomeSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

LUADTMEimmune cells

Substanzen

Bone Marrow Stromal Antigen 2BST2 protein, humanAntigens, CDGPI-Linked ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Affiliated LiHuiLi Hospital of Ningbo University, Ningbo, 315040, Zhejiang, China, nbu.edu.cn.

ORCID-Profile: Keyun Zhu, Mingrong Lin, Tao Hu, Zhikai Cao, Shuo Huang, Yan Shen, Jing Zeng, Jinxian He, Weiyu Shen, Jianjian Ying

Förderung

  • Natural Science Foundation of Ningbo
  • Medical Science and Technology Project of Zhejiang Province

Zitieren

APA

Zhu, K., Lin, M., Lin, C., Hu, T., Cao, Z., Huang, S., Shen, Y., Zeng, J., He, J., Shen, W., & Ying, J. (2026). Single‐Cell Transcriptomics Identifies BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/3777132

Vancouver

Zhu K, Lin M, Lin C, Hu T, Cao Z, Huang S, et al. Single‐Cell Transcriptomics Identifies BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/3777132

BibTeX
@article{Zhu2026,
  author = {Zhu, Keyun and Lin, Mingrong and Lin, Chengbin and Hu, Tao and Cao, Zhikai and Huang, Shuo and Shen, Yan and Zeng, Jing and He, Jinxian and Shen, Weiyu and Ying, Jianjian},
  title = {Single‐Cell Transcriptomics Identifies BST2 as an Oncogenic Driver and Immunotherapy Biomarker in Lung Adenocarcinoma},
  journal = {Mediators of Inflammation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/mi/3777132}
}
Kostenlos starten →